Lataa...
Could ketamine be the answer to treating treatment-resistant major depressive disorder?
Major depressive disorder (MDD) is a common, serious, debilitating condition affecting 350 million people worldwide, which remains to be unsatisfactorily treated with 53% of patients still complaining of symptoms after completing their courses with the correct dosage. Ketamine, which was approved by...
Tallennettuna:
| Julkaisussa: | Gen Psychiatr |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BMJ Publishing Group
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7437682/ https://ncbi.nlm.nih.gov/pubmed/32875273 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gpsych-2020-100227 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|